By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Standard & Poor's today raised its corporate credit rating on Bio-Rad Laboratories to "BBB" from "BBB-" with a stable outlook.

The credit rating service also said that it had raised Bio-Rad's senior subordinated rating to "BBB-" from "BB+".

"The upgrade reflects Bio-Rad's continued solid operating performance and cash flow generation, despite recent challenges in the life science industry," S&P Credit Analyst Arthur Wong said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.